<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent genome-wide association studies identified several novel risk genes for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of these type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk variants confer impaired pancreatic beta cell function </plain></SENT>
<SENT sid="2" pm="."><plain>Though the molecular mechanisms by which common genetic variation within these loci affects beta cell function are not completely understood, risk variants may alter <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion, proinsulin conversion, and incretin signals </plain></SENT>
<SENT sid="3" pm="."><plain>In humans, the incretin effect is mediated by the secretion and insulinotropic action of two <z:chebi fb="0" ids="25905">peptide hormones</z:chebi>, <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> and glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 </plain></SENT>
<SENT sid="4" pm="."><plain>This review article aims to give an overview of the type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> risk loci that were found to associate with incretin secretion or incretin action, paying special attention to the potential underlying mechanisms </plain></SENT>
</text></document>